Clinical Trials Browser

Phase 1 × capivasertib × Breast × Clear all

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1 Completed

BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)